A total of 230 patients with a serum phosphate 1.97 and < 3.23 mmol/L were randomized to JTT-751 ( dose adjusted between 1.5 and 6.0 g/day ) or sevelamer hydrochloride ( dose adjusted between 3.0 and 9.0 g/day ) for 12 weeks .